Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0013398
UniProt IDP21802
Primary gene name(s)FGFR2
Synonym gene name(s)BEK, KGFR, KSAM
Protein nameFibroblast growth factor receptor 2
Protein functionTyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. {ECO:0000269|PubMed:12529371, ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15629145, ECO:0000269|PubMed:16384934, ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19103595, ECO:0000269|PubMed:19387476, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:8663044}.
Subcellular locationCell membrane;
Single-pass type I membrane protein. Golgi apparatus. Cytoplasmic vesicle. Note=Detected on osteoblast plasma membrane lipid rafts. After ligand binding, the activated receptor is rapidly internalized and degraded.;
SUBCELLULAR LOCATION: Isoform 1: Cell membrane;
Single-pass type I membrane protein. Note=After ligand binding, the activated receptor is rapidly internalized and degraded.;
SUBCELLULAR LOCATION: Isoform 3: Cell membrane;
Single-pass type I membrane protein. Note=After ligand binding, the activated receptor is rapidly internalized and degraded.;
SUBCELLULAR LOCATION: Isoform 14: Secreted.;
SUBCELLULAR LOCATION: Isoform 19: Secreted.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P21802
Gene Ontology
(Biological Process)
Complete annatation
angiogenesis [GO:0001525];
animal organ morphogenesis [GO:0009887];
apoptotic process [GO:0006915];
axonogenesis [GO:0007409];
bone development [GO:0060348];
bone mineralization [GO:0030282];
bone morphogenesis [GO:0060349];
branch elongation involved in salivary gland morphogenesis [GO:0060667];
branching involved in labyrinthine layer morphogenesis [GO:0060670];
branching involved in prostate gland morphogenesis [GO:0060442];
branching involved in salivary gland morphogenesis [GO:0060445];
branching morphogenesis of a nerve [GO:0048755];
bud elongation involved in lung branching [GO:0060449];
cell-cell signaling [GO:0007267];
cell fate commitment [GO:0045165];
digestive tract development [GO:0048565];
embryonic cranial skeleton morphogenesis [GO:0048701];
embryonic digestive tract morphogenesis [GO:0048557];
embryonic organ development [GO:0048568];
embryonic organ morphogenesis [GO:0048562];
embryonic pattern specification [GO:0009880];
epidermis morphogenesis [GO:0048730];
epithelial cell differentiation [GO:0030855];
epithelial cell proliferation involved in salivary gland morphogenesis [GO:0060664];
epithelial to mesenchymal transition [GO:0001837];
fibroblast growth factor receptor signaling pathway [GO:0008543];
fibroblast growth factor receptor signaling pathway involved in hemopoiesis [GO:0035603];
fibroblast growth factor receptor signaling pathway involved in mammary gland specification [GO:0060595];
fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow [GO:0035602];
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development [GO:0035607];
fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow [GO:0035604];
gland morphogenesis [GO:0022612];
hair follicle morphogenesis [GO:0031069];
inner ear morphogenesis [GO:0042472];
in utero embryonic development [GO:0001701];
lacrimal gland development [GO:0032808];
lateral sprouting from an epithelium [GO:0060601];
limb bud formation [GO:0060174];
lung alveolus development [GO:0048286];
lung-associated mesenchyme development [GO:0060484];
lung development [GO:0030324];
lung lobe morphogenesis [GO:0060463];
mammary gland bud formation [GO:0060615];
MAPK cascade [GO:0000165];
membranous septum morphogenesis [GO:0003149];
mesenchymal cell differentiation [GO:0048762];
mesenchymal cell differentiation involved in lung development [GO:0060915];
mesenchymal cell proliferation involved in lung development [GO:0060916];
mesodermal cell differentiation [GO:0048333];
midbrain development [GO:0030901];
morphogenesis of embryonic epithelium [GO:0016331];
multicellular organism growth [GO:0035264];
negative regulation of epithelial cell proliferation [GO:0050680];
negative regulation of transcription from RNA polymerase II promoter [GO:0000122];
odontogenesis [GO:0042476];
orbitofrontal cortex development [GO:0021769];
organ growth [GO:0035265];
otic vesicle formation [GO:0030916];
outflow tract septum morphogenesis [GO:0003148];
peptidyl-tyrosine phosphorylation [GO:0018108];
phosphatidylinositol-mediated signaling [GO:0048015];
positive regulation of canonical Wnt signaling pathway [GO:0090263];
positive regulation of cardiac muscle cell proliferation [GO:0060045];
positive regulation of cell cycle [GO:0045787];
positive regulation of cell division [GO:0051781];
positive regulation of cell proliferation [GO:0008284];
positive regulation of epithelial cell proliferation [GO:0050679];
positive regulation of epithelial cell proliferation involved in lung morphogenesis [GO:0060501];
positive regulation of ERK1 and ERK2 cascade [GO:0070374];
positive regulation of MAPK cascade [GO:0043410];
positive regulation of mesenchymal cell proliferation [GO:0002053];
positive regulation of phospholipase activity [GO:0010518];
positive regulation of smooth muscle cell proliferation [GO:0048661];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
positive regulation of Wnt signaling pathway [GO:0030177];
post-embryonic development [GO:0009791];
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis [GO:0060527];
prostate epithelial cord elongation [GO:0060523];
prostate gland morphogenesis [GO:0060512];
protein autophosphorylation [GO:0046777];
pyramidal neuron development [GO:0021860];
regulation of branching involved in prostate gland morphogenesis [GO:0060687];
regulation of cell fate commitment [GO:0010453];
regulation of ERK1 and ERK2 cascade [GO:0070372];
regulation of fibroblast growth factor receptor signaling pathway [GO:0040036];
regulation of morphogenesis of a branching structure [GO:0060688];
regulation of multicellular organism growth [GO:0040014];
regulation of osteoblast differentiation [GO:0045667];
regulation of osteoblast proliferation [GO:0033688];
regulation of phosphatidylinositol 3-kinase signaling [GO:0014066];
regulation of smoothened signaling pathway [GO:0008589];
regulation of smooth muscle cell differentiation [GO:0051150];
reproductive structure development [GO:0048608];
skeletal system morphogenesis [GO:0048705];
squamous basal epithelial stem cell differentiation involved in prostate gland acinus development [GO:0060529];
ureteric bud development [GO:0001657];
ventricular cardiac muscle tissue morphogenesis [GO:0055010];
ventricular zone neuroblast division [GO:0021847]
Gene Ontology
(Molecular Function)
Complete annatation
1-phosphatidylinositol-3-kinase activity [GO:0016303];
ATP binding [GO:0005524];
fibroblast growth factor-activated receptor activity [GO:0005007];
fibroblast growth factor binding [GO:0017134];
heparin binding [GO:0008201];
phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934];
protein homodimerization activity [GO:0042803];
protein tyrosine kinase activity [GO:0004713];
Ras guanyl-nucleotide exchange factor activity [GO:0005088]
Gene Ontology
(Cellular Component)
Complete annatation
cell cortex [GO:0005938];
cell surface [GO:0009986];
cytoplasm [GO:0005737];
cytoplasmic, membrane-bounded vesicle [GO:0016023];
excitatory synapse [GO:0060076];
extracellular region [GO:0005576];
Golgi apparatus [GO:0005794];
integral component of membrane [GO:0016021];
integral component of plasma membrane [GO:0005887];
intracellular membrane-bounded organelle [GO:0043231];
membrane [GO:0016020];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
plasma membrane [GO:0005886]
Protein-protein interaction108554
Phylogenetic treeP21802
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3unknownunknownunknown
AZA vs. DISUunknownunknownunknown
AZA vs. IL7unknownunknownunknown
AZA vs. SAHAunknownunknownunknown
DISU vs. CD3unknownunknownunknown
DISU vs. IL7unknownunknownunknown
DISU vs. SAHAunknownunknownunknown
DMSO vs. AZAunknownunknownunknown
DMSO vs. CD3unknownunknownunknown
DMSO vs. DISUunknownunknownunknown
DMSO vs. IL7unknownunknownunknown
DMSO vs. SAHAunknownunknownunknown
HIV vs. Mock in Activationunknownunknownunknown
HIV vs. Mock in Latency0.350032094310820.5440843830998740.999834320637052
IL7 vs. CD3unknownunknownunknown
SAHA vs. CD3unknownunknownunknown
SAHA vs. IL7unknownunknownunknown
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
NOTEST -1.53692 1
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00039 Palifermin approved yes binder
DB02491 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine experimental unknown unknown
DB02058 SU4984 experimental unknown unknown
DB01041 Thalidomide approved, investigational, withdrawn yes antagonist
DB08896 Regorafenib approved yes inhibitor
DB08901 Ponatinib approved unknown inhibitor
DB09078 Lenvatinib approved yes Inhibitor
DB09079 Nintedanib approved yes Inhibitor

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1DJS X-ray 2.4Å A=32-362.
1E0O X-ray 2.8Å B/D=148-366.
1EV2 X-ray 2.2Å E/F/G/H=147-366.
1GJO X-ray 2.4Å A=456-768.
1II4 X-ray 2.7Å E/F/G/H=147-366.
1IIL X-ray 2.3Å E/F/G/H=147-366.
1NUN X-ray 2.9Å B=140-368.
1OEC X-ray 2.4Å A=456-768.
1WVZ NMR - A=147-249.
2FDB X-ray 2.2Å P/R=149-368.
2PSQ X-ray 2.4Å A/B=413-768.
2PVF X-ray 1.8Å A=458-778# B=764-778.
2PVY X-ray 2.2Å A/B/C/D=458-768.
2PWL X-ray 2.4Å A/B=458-768.
2PY3 X-ray 2.3Å A/B=458-768.
2PZ5 X-ray 2.4Å A/B=458-768.
2PZP X-ray 2.4Å A/B=458-768.
2PZR X-ray 3.0Å A/B=458-768.
2Q0B X-ray 2.9Å A/B=458-768.
3B2T X-ray 1.8Å A/B=458-766.
3CAF X-ray 1.9Å A=150-249.
3CLY X-ray 2.0Å A=458-778.
3CU1 X-ray 2.6Å A/C=150-249.
3DAR X-ray 2.2Å A/B=146-249.
3EUU X-ray 2.3Å A/B=150-249.
3OJ2 X-ray 2.2Å C/D=140-313.
3OJM X-ray 2.1Å B=140-313.
3RI1 X-ray 2.1Å A/B=458-768.
4J23 X-ray 3.8Å A=147-366.
4J95 X-ray 2.3Å A/B/C/D=458-768.
4J96 X-ray 2.3Å A/B=458-768.
4J97 X-ray 2.5Å A/B/C/D=458-768.
4J98 X-ray 2.3Å A/B=458-768.
4J99 X-ray 1.8Å A/B/C/D=458-768.
4WV1 X-ray 2.3Å C/F=153-251.
5EG3 X-ray 2.6Å A=458-778.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa01521 EGFR tyrosine kinase inhibitor resistance - Homo sapiens (human)
hsa04010 MAPK signaling pathway - Homo sapiens (human)
hsa04014 Ras signaling pathway - Homo sapiens (human)
hsa04015 Rap1 signaling pathway - Homo sapiens (human)
hsa04144 Endocytosis - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04550 Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human)
hsa04810 Regulation of actin cytoskeleton - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05215 Prostate cancer - Homo sapiens (human)
hsa05230 Central carbon metabolism in cancer - Homo sapiens (human)
Menu